Package Leaflet: Information for the User
Alercina 10 mg Tablets
cetirizine dihydrochloride
Read this package leaflet carefully before starting to take this medicine, as it contains important information for you.
Follow the administration instructions of the medicine contained in this package leaflet or as indicated by your doctor or pharmacist.
Contents of the Package Leaflet
The active ingredient of Alercina is cetirizine dihydrochloride.
Alercina is an antiallergic medicine.
It is indicated for the relief of nasal and ocular symptoms of seasonal and perennial allergic rhinitis in adults, adolescents, and children from 6 years of age.
You should consult a doctor if it worsens or does not improve after 3 days.
Do not take Alercina
Warnings and Precautions
Consult your doctor or pharmacist before starting to take Alercina.
If you are a patient with renal insufficiency, consult your doctor; if necessary, you will take a lower dose. Your doctor will determine the new dose.
If you are an epileptic patient or a patient at risk of convulsions, consult your doctor.
No interactions likely to have a significant impact have been observed between alcohol (with a blood level of 0.5 per thousand, corresponding to a glass of wine) and the use of cetirizine at normal doses. However, as with all antihistamines, it is recommended to avoid concurrent consumption of alcohol during treatment.
Other Medicines and Alercina
Tell your doctor or pharmacist if you are taking, have recently taken, or may need to take any other medicine.
Taking Alercina with Food and Drinks
Taking this medicine with food and drinks does not affect its efficacy.
Pregnancy and Breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medicine.
You should not take this medicine during breastfeeding, as cetirizine passes into breast milk.
Driving and Using Machines
Clinical studies have not shown evidence that Alercina causes alterations in attention, decreased reaction capacity, and ability to drive at the recommended dose.
If you plan to drive, perform potentially hazardous activities, or use machinery, do not exceed the recommended dose. You should closely observe your response to the medicine.
If you are a sensitive patient, you may find that simultaneous use of alcohol or other central nervous system depressants may also affect your attention and reaction capacity.
If during treatment with this medicine you notice dizziness or drowsiness, you should not drive.
Alercina contains Lactose.
This medicine contains lactose. If your doctor has told you that you have an intolerance to certain sugars, consult with them before taking this medicine.
Follow the administration instructions of the medicine contained in this package leaflet or as indicated by your doctor or pharmacist. In case of doubt, ask your doctor or pharmacist.
The recommended dose is:
Adults and Adolescents over 12 years
1 tablet of 10 mg, 1 time a day.
Children between 6 and 12 years
Half a tablet (5 mg), 2 times a day.
Patients with Moderate to Severe Renal Insufficiency
It is recommended that patients with moderate renal insufficiency take half a tablet (5 mg) 1 time a day.
How to take
The tablets should be swallowed with a glass of liquid.
You should consult a doctor if it worsens or does not improve after 3 days of treatment.
If you take more Alercina than you should
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, phone 91 562 04 20, indicating the medicine and the amount ingested.
After an overdose, you may notice confusion, diarrhea, dizziness, fatigue, headache, weakness, pupil dilation, tingling, irritation, sedation, drowsiness, stupor, abnormal increase in heart rate, tremor, and urinary retention.
If you forget to take Alercina
Do not take a double dose to make up for forgotten doses.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
The following side effects have occurred:
Common(may affect up to 1 in 10 people): fatigue, dizziness, headache, diarrhea, dry mouth, nausea, drowsiness, pharyngitis, rhinitis.
Uncommon(may affect up to 1 in 100 people): asthenia (extreme fatigue), malaise, paresthesia (abnormal skin sensation), abdominal pain, agitation, pruritus, rash.
Rare(may affect up to 1 in 1,000 people): edema (swelling), convulsions, movement disorders, aggression, confusion, depression, hallucination, insomnia, allergic reactions, some severe (very rare), tachycardia (heart beats too fast), abnormal liver function, urticaria, weight gain.
Very Rare(may affect up to 1 in 10,000 people): syncope, tremor, dysgeusia (taste disorder), tic, thrombocytopenia (low blood platelet levels), accommodation disorders, blurred vision, ocular gyration (eyes have uncontrolled circular movement), edema, drug eruption, abnormal urine elimination.
Reporting of Side Effects
If you experience any side effects, consult your doctor or pharmacist, even if they are possible side effects not listed in this package leaflet. You can also report them directly through the Spanish Medicines and Healthcare Products Agency (AEMPS) website: http://www.aemps.gob.es. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
This medicine does not require special storage conditions.
Do not use this medicine after the expiration date stated on the packaging after CAD. The expiration date is the last day of the month indicated.
Medicines should not be disposed of via wastewater or household waste. Place the packaging and any unused medicines in the pharmacy's SIGRE point. If in doubt, ask your pharmacist how to dispose of the packaging and any unused medicines. This will help protect the environment.
Alercina Composition
The active ingredient is cetirizine dihydrochloride. Each tablet contains 10 mg of cetirizine dihydrochloride.
The other ingredients are:
Product Appearance and Package Contents
Alercina are film-coated, cylindrical, biconvex, scored tablets, white in color, and marked with the code “C”.
They are presented in PVC-PVDC/Aluminum blisters and are available in packs with 7 tablets.
Marketing Authorization Holder and Manufacturer
Laboratorios Cinfa, S.A.
Carretera Olaz-Chipi, 10. Polígono Industrial Areta
31620 Huarte (Navarra) – Spain
Date of the Last Revision of this Package Leaflet:June 2023
Detailed information on this medicine is available on the website of the Spanish Agency for Medicines and Healthcare Products (AEMPS) http://www.aemps.gob.es